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A B S T R A C T
Objective: To determine the required learning time for high-resolution anoscopy (HRA)-guided biopsy to detect
histological high-risk squamous intraepithelial lesions (hHSIL) and to identify factors that impact on the training
process.
Methods: All HIV-infected, screening-naïve men-who-have-sex-with-men who underwent HRA conducted by one
single observer from 2010 to 2017 in a Spanish HIV-outpatient clinic were analysed.
Results: Eighty-five (14.7%) of the 581 patients included presented hHSIL. The factors associated with the ca-
pacity to detect hHSIL [adjusted odds ratio (aOR), 95% confidence interval (95%CI)] were the presence of
cytological HSIL (3.04, 1.78–5.21; p < 0.001), infection with high-risk human papilloma virus (HR-HPV) (2.89,
1.38–6.05; p= 0.005), the number of biopsies taken/HRA (aOR: 1.28, 1.07–1.52; p= 0.006) and tobacco
smoking (1.75; 1.12–2.73; p=0.014). Two events independently augmented the detection rate of hHSIL: one
single experienced pathologist interpreted biopsies after 409 HRA (2.80, 1.74–4.48; p= 0.035) and the anos-
copist underwent an additional training after 536 HRA (2.57, 1.07–6.16; p= 0.035). A learning process could be
observed throughout the whole study with stable HR-HPV prevalence.
Conclusion: The data support the growing evidence that the proposed training volume of 50–200 performances is
underestimated. Extensive training of both anoscopist and pathologist is warranted and the development of tools
to support the diagnostic performance may be considered.
1. Introduction
The incidence of anal cancer is progressively increasing, especially
among patients at risk, such as HIV-infected men who have sex with
men (MSM). In this specific population, incidences of up to 100 cases
per 100,000 person-years (py) have been reported, as compared to 1.2
cases per 100,000 py in the overall population [1–3]. Similar to what is
widely known for cervical cancer, there is extensive evidence that the
development of anal cancer is preceded by high-grade squamous in-
traepithelial lesions (HSIL) caused by high-risk human papillomavirus
(HR-HPV) genotype infection [4–6] which is frequently found in MSM
[7].
High-resolution anoscopy (HRA) is currently considered the gold
standard for the diagnosis of HSIL [8]. HRA consists of visualizing
potentially precancerous lesions with acetic acid and Lugol's solution
using a colposcope or anoscope, with subsequent confirmation by
means of one or more biopsies. Although the procedure itself is very
similar to comparatively simple cervical colposcopy, HRA is char-
acterised by a long learning curve due to the anatomical topography of
the anus and several factors that may obscure lesions such as folds,
mucus, or haemorrhoids [9,10]. Thus, HRA requires extensive training
and observer experience in order to warrant that HSIL do not go un-
noticed. While the International Anal Neoplasia Society (IANS) re-
commends a learning period of 50–100 HRA [10], contradictory data
was obtained by other studies [11–13] and it remains unknown which
factors influence the learning progression.
Therefore, this study aimed to assess the training process over time
for one single observer performing HRA in HIV-infected MSM, as well
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as to identify parameters that may impact on the outcome.
2. Patients and methods
2.1. Study population
This retrospective analysis of the prospective Seville Cohort of
People Living with HIV at Risk for Anal Cancer (SeVIHanal Cohort,
clinicaltrials.gov: NCT03713229) was conducted at a Spanish tertiary
care centre in which 2500 HIV-infected patients are followed on a
regular basis. From September 2010 until July 2017, all HIV-infected
MSM attended at one medical office were invited to be screened for
HSIL by means of HRA with biopsy. In the present study, the inclusion
criteria were: patients older or equal than 18 years who for the first
time underwent HRA with subsequent anal biopsy conducted by one
single observer and who had no prior test for anal lesions including
digital-rectal examination, HPV testing or anal liquid-based cytology
(aLBC). According to the protocol followed, the same day all patients
had a HR-HPV testing and an aLBC prior to HRA. Likewise, clinical and
epidemiological data were prospectively entered in electronic medical
records (ACyH1, Betek 43 SL, Spain).
2.2. Anoscopy/biopsy, aLBC and HPV genotyping performance and
interpretation
Before starting the HSIL screening program, the observer carried out
a study on the prevalence of HPV in HIV-infected MSM and received a
one-day theoretical and practical training by a provider from the
Callen-Lorde Centre, New York, with more than five years experience in
HRA and training. Both activities were promoted by the Spanish HIV
Investigation Network (RIS). HRA was performed according to the
training with the support of further guiding material1. Briefly, after
aLBC and HR-HPV testing, the patients were examined in the left lateral
recumbent position with a lubricated/lidocaine gel treated anoscope
(OCS-500, Olympus Medical Systems, Tokyo, Japan). Biopsies were
taken with 3mm Baby Tischler's forceps from areas considered ab-
normal by the observer after treatment with 3–5% acetic acid and Lu-
gol's solution and subsequently analysed by a histologist blinded to the
cytology/HPV results. If more than one biopsy was obtained, the
highest degree of abnormality found was used as the histological di-
agnosis. Biopsy readings were performed using standard laboratory
protocols and differentiated “normal”, low-grade anal intraepithelial
neoplasia (“LSIL”) which includes condyloma and anal intraepithelial
neoplasia (AIN) grade I, as well as “HSIL” which includes AIN grade II
and III [14]. aLBC (ThinPrep®/ PerservCyt® solution, Hologic Inc,
Barcelona, Spain) and HPV genotyping were carried out as described
elsewhere [15]. Cytological HSIL was diagnosed according to the Be-
thesda System as encompassing moderate and severe dysplasia [16].
HPV genotypes classified as “carcinogenic” (HPV 16, 18, 31, 33, 35, 39,
45, 51, 52, 56, 58, 59) or “probably carcinogenic” (HPV 68) to humans
according to the International Agency for Research on Cancer were
considered HR-HPV [17].
2.3. Statistical analysis
Continuous variables were expressed as median and interquartile
range (IQR) and categorical variables as the number of cases and per-
centages. The outcome variable was the detection of histological HSIL,
as diagnosed by means of HRA with subsequent biopsy. Variables that
potentially influence the outcome variable were analysed using the chi-
square or the Fisher's test when categorical and the Student's t-test or
the Mann–Whitney test when continuous. Two events with potential
impact on the learning curve were analysed: While initially, all biopsies
were interpreted by a team of three pathologists, only one single spe-
cially trained expert pathologist was responsible for all biopsy readings
(Event#1) and the anoscopist underwent an additional three-day
“Advanced HRA Course” organized by the IANS (San Francisco, CA)
(Event#2), which consisted of an advanced training program for ob-
servers with an experience of a recommended 100–200 or more con-
ducted HRAs. Prevalence of histological findings, aLBC and HR-HPV
were calculated for the overall population and by the main stages de-
fined for the referred events.
To compare the main slopes of the learning curve for the detection
of HSIL, a linear regression model was set, including events con-
comitant with slopes changes. Linear binomial models were used to
identify factors that independently impact on the detection of HSIL. The
complementary log-log link function was selected since the outcome
variable was expected to be disproportioned, including all variables
with a p-value below 0.2 in the univariate analysis. Continuous vari-
ables were transformed when necessary to satisfy model assumptions.
The Akaike Information Criterion (AIC) was used to assess which model
best explained the detection of HSIL: the lower the AIC value, the better
the fit. To calculate how many times one model is better than the other,
the neperian antilogarithm was calculated according to the following
formula: 1/[exp (- (AIC model 2 -AIC model 1)/2)]. Statistical analyses
were performed using the SPSS v. 21.0 software (IBM, Chicago, USA)
and R Statistical Software (Foundation for Statistical Computing,
Vienna, Austria). P-values below 0.05 were considered significant.
2.4. Ethics approval and consent to participate
The study was designed and performed according to the Helsinki
declaration and was approved by the Ethics Committee of the Virgen
del Rocío University Hospital (Seville, Spain; Ref. 03/2006). All pa-
tients gave their written informed consent both to be included in the
database, as well as to the use of their anonymised data, photographies
or videoscopies for scientific research and HRA training programs,
thereby ensuring the protection of personal data in accordance with the
Spanish Personal Data Protection Organic Law15/199 enacted on
December 13, 1999.
3. Results
3.1. Characteristics of the study population
A total of 581 HIV-infected MSM who firstly underwent HRA were
included in the analysis, of whom 405 subjects had an undetectable
plasma HIV RNA from a median (IQR) time of 17 (8−37) months. The
median (IQR) CD4+ T-cell count was 630 (483−800) cells/μL. Further
characteristics of the study population are shown in Table 1.
3.2. Results of anal mucosa biopsy, aLBC and HPV genotyping
The histological results in the overall population were as follows:
normal, 235 (40.4%); LSIL (AIN grade I and condyloma), 192 (33.1%);
AIN grade II, 59 (10.2%) and AIN grade III, 26 (4.5%), while 69
(11.9%) samples were not valid. Thus, a total of 85/581 HRA (14.6%)
had a histological HSIL diagnosis. The HSIL prevalences before
Event#1, between Event#1 and Event#2 and after Event#2 were 38/
409 HRA (9%), 29/127 HRA (23%) and 18/45 HRA (39%), respec-
tively, p < 0.001. The corresponding prevalences for non-valid biop-
sies were 12.2%, 12.6% and 6.7%, respectively [p (before Event#1
versus after Event #2)< 0.001]. HPV genotyping was available in 560
(96.4%) patients, of which 428 (76.4%) individuals showed a HR-HPV.
Histologic HSIL was observed in 70 (16.4%) of those with HR-HPV
versus 8 (6.1%) subjects without HR-HPV, p=0.003. Fifty (9%) out of
557 patients with a valid aLBC showed cytological HSIL. Of those with
cytological HSIL, 18 (36%) patients also showed histological HSIL
versus 61 (12%) patients without HSIL in aLBC, p < 0.001. The1 A review on HRA technique that was used for guidance.
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corresponding figures for smokers versus non-smokers were 34 (18.3%)
versus 51 (12.9%), p=0.102, and where one, two, three or four biopsy
samples were taken per HRA, HSIL was detected in 71 (12.8%), 9
(50%), 3 (60%) and 2 (100%) individuals, p < 0.001. Median (IQR)
age was 37 (29−46) years and 39 (32−47) years in patients with and
without HSIL, p= 0.148.
3.3. Predictive factors for the detection of HSIL
In an univariate analyses, the following factors were associated with
a p < 0.2 with the detection of HSIL: the presence of HSIL in aLBC
(crude OR: 3.48, 95%CI: 2.05–5.91 p < 0.001), the presence of HR-
HPV (crude OR: 2.86, 95%CI: 1.37–5.94, p= 0.005), the number of
biopsies taken per HRA (crude OR: 1.43, 95%CI: 1.26–1.63,
p < 0.001), age (crude OR: 0.84, 95%CI: 0.67–1.04, p= 0.108), ac-
cumulated number of HRA (crude OR: 1.51, 95%CI: 1.21–1.89,
p < 0.001) and accumulated number of HRA by events: Event#1 vs
no-event (crude OR: 2.50, 95%CI: 1.56–4.04, p < 0.001) and Event#2
vs no-event (crude OR: 4.97, 95%CI: 2.79–8.85, p < 0.001). Regarding
the demographic or HIV-related factors associated with presence of
histological HSIL, only tobacco smoking showed a positive trend (crude
OR: 1.46, 95%CI: 0.95–2.26, p=0.088). There were no differences
with a statistical significance of p < 0.2 for CD4+ T-cell count nadir or
at time of intervention, CD4+/CD8+ ratio, presence of or time of un-
detectable plasma HIV RNA, presence of gonorrhoea/chlamydia, nor
CDC category C.
In the binomial regression models, the highest AOR were associated
with the presence of HSIL in aLBC, the presence of HR-HPV, as well as
the accumulated number of HRA (Model 1) and Event#1 and Event#2
(Model 2) (Fig. 1). Based on the AIC fit index, Model 2, including
concomitant events with slope changes showed a 90.02-fold better fit
than Model 1.
3.4. Learning curve
The accumulated numbers of HSIL detected with increasing number
of total HRA conducted, as well as the prevalence of HR-HPV over the
study time, are depicted in Fig. 2. There were three mains slopes for the
detection of HSIL. The second slope was observed after 409 HRAs and
the third slope after 536 HRAs. Both slopes were steeper compared to
the first one, with differences of 5.40 and 22.11 in histological HSIL
(p < 0.001), respectively. The emergence of both slopes could be at-
tributed to Event#1 and Event#2. The slope of the concomitant HR-
HPV prevalence curve was negative (-0.0003) and liner (r2 = 0.97)
after a considerable number (100 HRA) to calculate the prevalence of
HR-HPV at every HRA conducted was reached.
4. Discussion
The present study confirms a long learning curve for HRA and,
furthermore, the data suggest that the amount of training recommended
by different guidelines may not be sufficient [8]. To our knowledge, this
is the first study to determine factors that impact on the learning pro-
cess and underlines the importance of both training and experience not
only of the anoscopist but also of the pathologist, which should be taken
into account when performing HRA.
Up to the end of the study where almost 600 HRA had been per-
formed, a learning process could be observed as indicated by the lack of
a plateau on the learning curve that would represent the moment of the
detection of a constant number of HSIL. Data on observer experience in
HRA are scarce and include small and/or heterogeneous populations.
Furthermore, in these studies a concomitant cytology outcome is
mainly used to validate HRA in spite of the considerably poor diag-
nostic values of aLBC, which may result in misleading interpretations
[8]. In this context, a study conducted in 384 MSM suggests a training
period of 200 HRA as sufficient to consider that the observer obtained
sufficient experience [11]. It is to note though that, even after that
point, a learning phase could be observed visually in the learning curve
but, unfortunately, statistical analysis was not done in the study.
Likewise, data from another study that measured the diagnostic per-
formance of HRA by the concordance between cytological and histo-
logical diagnosis suggested that the results can improve when training
is continued to 800 interventions [13]. Finally, our findings are in ac-
cordance to a recent study conducted by Hillmann et al. suggesting that
a minimum of 500 procedures are needed for an anoscopist to reach
maximum achievable diagnostic accuracy [12]. In contrast to that
study, in the present study only patients without prior data acquisition
were included in order to avoid biases. All this suggests that the already
considerably high training period of 50–200 procedures as suggested by
expert panels [8–10] may still not be sufficient. To solve this problem,
the development of tools to shorten the learning process and facilitate
the identification of sites were biopsies should be taken, such as the use
of computer algorithms to process HRA based on artificial intelligence,
are warranted.
In addition to the constant learning process due to acquisition of
experience, two events significantly marked an increase in the diag-
nostic performance, one was based on the observer performing HRA,
but the other was not. This is an important finding since it points out
that, on the one hand, adequate teaching of the observer is crucial and
still effective after a considerable training period. In fact, a further
training within an advanced program (Event #2) was independently
associated with higher performance. It is to note that this program
addressed anoscopists with an experience in the range of the minimum
recommended training period as mentioned above, thus further un-
derlining the probable underestimation of 50–100 HRA to be sufficient
for reaching expert status. Also, the proportion of invalid biopsies de-
creased almost 50% to a number representative for expert anoscopists.
On the other hand, the data show the importance of factors associated
with learning process and that may not be appreciated as they are less
obvious, such as the training and skills of the pathologist. Both events
were observed independently from other known factors associated with
HSIL such as the presence of HSIL in cytology and HR-HPV and, to a
lower extent, smoking [18]. To our knowledge, the pathologist's ex-
perience is not considered in the currently available studies on the
learning process for HRA but should be taken into account in the future.
This study has several limitations. First, since HRA is currently
considered the gold standard [8], there was no optimum measure to
confirm the HRA results. However, there is a very high association
between HR-HPV genotypes and anal cancer [18] and the proportion of
patients with HR-HPV did not only remain stable when a reasonable
number of patients was reached, there was also even a trend of a
Table 1
Characteristics of the study population (n=581) at the moment of high re-
solution anoscopy performance.
Characteristic Value
Age, yearsa 38 (31–47)








Undetectable plasma HIV RNA, n (%) 405 (69.7)
CD4+ T-cell nadir, cells/μLa 290 (187–404)
C4+/CD8+ ratioa 0.68 (0.45–0.91)
CDC category C, n (%) 61 (10.5)
Gonorrhoea and/or chlamydia, n (%)b 40 (12.6)
a median (interquartile range).
b available in 370 patients.
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descending prevalence of HR-HPV over time. Therefore, it can be as-
sumed that the proportion of patients with HGAIN was similar
throughout the study period and if there was a change it would have
been in a way that at the end of the study the prevalence would have
been lower. This would make it even more difficult to detect HSIL,
however, the learning curve clearly steepened towards the end, in-
dicating more HSIL detection per number of HRA. Second, data of only
one observer was analysed. Still, as mentioned above, the results of the
present study are similar to what was described earlier and it is
therefore likely that the results represent an adequate approximation of
the general population. Finally, following the advanced training, the
concentration of acetic acid used in HRA was enhanced from 3% to 5%
in order to improve visibility of HSIL. However, while this may con-
tribute to a higher yield of detected HSIL, the crucial point is the in-
terpretation of what is visualized, depending on the observer's skills.
Therefore, the use of a different concentration merely represents part of
the training as it is linked with its interpretation. The considerable
decrease in the proportion of invalid biopsies further confirms the
learning effect of the additional training.
In conclusion, the findings described herein support the growing
evidence that the widely proposed training volume is underestimated.
Extensive training of both anoscopist and pathologist is warranted and
the development of observer-independent visualization tools based on
Fig. 1. Binominal linear models to identify independent predictors for the detection of high-grade squamous intraepithelial lesions (HSIL) in high resolution an-
oscopies (HRA) with subsequent biopsy considering the number of HRA performed (Model 1, Fig. 2A) and the events that showed an impact on slope steepness of the
learning curve (Model 2, Fig. 2B) in HIV-infected men who have sex with men seen between 2010 and 2017 in an HIV outpatient clinic of a tertiary care centre in
Seville, Spain. AOR: adjusted odds ratio; CI: confidence interval; HR-HPV: high-risk human papillomavirus; Event #1: One single expert pathologist responsible for
biopsy interpretation; Event #2: Observer participates at additional one week expert training. Akaike Information Criteria were 389,398 for Model 1 and 380.526 for
Model 2, respectively.
Fig. 2. Accumulated high-grade anal squamous neoplasias (HSIL) according to
the total number of high resolution anoscopies (HRA) with subsequent biopsy
(black line) and the prevalence of high-risk human papillomavirus (HR-HPV)
(grey line) in 581 HIV-infected men who have sex with men seen between 2010
and 2017 in an HIV outpatient clinic of a tertiary care centre in Seville, Spain.
Event #1: One single expert pathologist responsible for biopsy interpretation;
Event #2: Observer participates at additional one week expert training. The
slope of the HR-HPV curve from the hundredth HRA onwards was −0.0003 (r2
= 0.97).
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